StockpollyBeta
Get App

Categories

Biotech

Companies that use biotechnology such as gene recombination, cell fusion, and nuclear transfer to develop new drugs and breeds.

+1.32% today·623 stocks·3 sub-categories

Stocks

By market cap · 623 stocks

  1. 1ABBVAbbVieImmunology drugmaker behind Skyrizi, Rinvoq, and Botox$467.37B+0.65%
  2. 2MRKMerckMaker of Keytruda, vaccines, and animal medicines$369.24B+2.19%
  3. 3NVSNovartis (ADR)Developer of focused innovative medicines$267.96B+0.49%
  4. 4AZNAstraZeneca (ADR)Oncology-led developer of specialty medicines$260.70B+0.48%
  5. 5TMOThermo Fisher ScientificScientific tools and outsourced biopharma services$244.81B+0.45%
  6. 6AMGNAmgenMaker of Prolia, Repatha, and rare-disease medicines$212.19B+4.09%
  7. 7GILDGilead SciencesDeveloper of HIV, liver-disease, and cancer medicines$186.93B+1.04%
  8. 8PFEPfizerDeveloper of Eliquis, Prevnar and cancer medicines$158.10B+0.83%
  9. 9BMYBristol-Myers SquibbDeveloper of Eliquis, Opdivo and specialty medicines$127.91B+0.42%
  10. 10GSKGSK (ADR)Developer of Shingrix, Nucala, and Trelegy$102.34B−0.33%
  11. 11REGNRegeneronMaker of Dupixent, EYLEA HD, and Libtayo$82.23B+0.77%
  12. 12MRNAModernaDeveloper of mRNA vaccines and therapeutics$68.62B+7.43%
  13. 13ARGXargenx (ADR)Developer of VYVGART autoimmune medicines$61.45B−1.20%
  14. 14AAgilent TechnologiesLaboratory instruments, diagnostics, and CrossLab services$45.75B+2.27%
  15. 15IQVIQVIAHealthcare intelligence and outsourced clinical research$44.42B+0.74%
  16. 16RVMDRevolution MedicinesDeveloper of RAS(ON) oncology candidates$40.98B+1.13%
  17. 17ONCBeOne Medicines (ADR)Developer of BRUKINSA and TEVIMBRA oncology medicines$39.07B−0.90%
  18. 18ALNYAlnylam PharmaceuticalsRNAi medicines built around gene-silencing delivery$32.69B+3.35%
  19. 19BIIBBiogenNeuroscience medicines across MS and rare disease$32.37B+2.98%
  20. 20ROIVRoivant SciencesVant-based developer of immunology medicines$28.17B−0.53%
  21. 21LHLabcorpClinical diagnostics and drug-development laboratory services$26.32B−3.78%
  22. 22INSMInsmedTwo marketed pulmonary medicines and gene therapies$26.23B−0.86%
  23. 23RPRXRoyalty PharmaBuyer and funder of drug royalties$25.90B+0.41%
  24. 24INCYIncyteJakafi-led hematology, oncology, and immunology drug developer$25.27B+1.42%
  25. 25BNTXBioNTech (ADR)Comirnaty developer with an oncology pipeline$24.62B+4.28%
  26. 26GMABGenmab (ADR)Builder of antibody medicines and bispecific platforms$21.30B+1.05%
  27. 27UTHRUnited TherapeuticsMaker of Tyvaso and investigational organ alternatives$20.93B+0.47%
  28. 28VTRSViatrisGlobal maker of established brands and generics$19.91B+0.46%
  29. 29MEDPMedpaceFull-service clinical trials for emerging biopharma sponsors$17.42B+0.14%
  30. 30JAZZJazz PharmaceuticalsSleep, epilepsy and oncology rare-disease medicines$15.17B+0.26%
  31. 31NBIXNeurocrine BiosciencesDeveloper of INGREZZA and rare-disease medicines$14.48B−0.71%
  32. 32EXELExelixisBuilder of the cabozantinib oncology franchise$14.38B+2.83%
  33. 33SMMTSummit TherapeuticsDeveloper of ivonescimab for solid tumors$13.48B+2.25%
  34. 34CRLCharles River LaboratoriesResearch models and nonclinical drug-development testing$13.44B+2.74%
  35. 35HALOHalozyme TherapeuticsENHANZE platform for subcutaneous drug delivery$13.22B+1.78%
  36. 36BBIOBridgeBio PharmaAttruby-led genetic disease drug developer$13.04B+3.86%
  37. 37ICLRICONOperator of global drug and device trials$12.98B−0.03%
  38. 38BMRNBioMarinRare-disease therapies spanning enzymes and skeletal conditions$12.38B+0.83%
  39. 39MDGLMadrigal PharmaceuticalsMASH drug developer behind Rezdiffra$12.06B−0.17%
  40. 40BAXBaxter InternationalHospital infusion, connected-care, and injectable products$11.85B+3.75%
  41. 41TECHBio-TechneMaker of life-science reagents and protein-analysis tools$11.35B+0.11%
  42. 42AXSMAxsome TherapeuticsCNS medicines for depression, agitation, sleepiness, and migraine$10.57B+0.18%
  43. 43TWSTTwist BioscienceSilicon-based DNA synthesis and sequencing tools$10.33B+1.23%
  44. 44RGENRepligenBioprocessing tools for biologics manufacturing$10.20B+3.33%
  45. 45KRYSKrystal BiotechTopical VYJUVEK and redosable genetic medicine pipeline$9.84B+5.41%
  46. 46ARWRArrowhead PharmaceuticalsDeveloper of targeted RNAi medicines$9.69B+3.97%
  47. 47KYMRKymera TherapeuticsOral protein degraders for immunological diseases$9.68B+3.31%
  48. 48PTGXProtagonist TherapeuticsPeptide-drug developer behind ICOTYDE and rusfertide$9.32B+0.93%
  49. 49IBRXImmunityBioMaker of ANKTIVA and cellular immunotherapies$8.85B+4.37%
  50. 50TGTXTG TherapeuticsCommercializer of BRIUMVI for relapsing multiple sclerosis$8.75B+1.10%